XTX Markets’s Vertex Pharmaceuticals VRTX Stock Holding History

XTX Markets’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,572	Closed	-$428K	–	259
2020 Q3	$428K	Buy	+1,572	New	+$434K	2.06%	5

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

XTX Markets's VRTX Position: Q4 2020 in Review

XTX Markets sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 1,572 shares — an estimated $428K sold.

XTX Markets first reported a position in VRTX in Q3 2020 and held it in 1 quarter. The position peaked at $428K in Q3 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

XTX Markets reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
XTX Markets sold 1,572 Vertex Pharmaceuticals shares in Q4 2020, an estimated $428K.
XTX Markets first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 1 quarter.
XTX Markets's Vertex Pharmaceuticals position peaked at $428K in Q3 2020.
971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.